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Tuberculosis (TB) is a serious public health problem in the UK, and detection and prophylactic 
treatment of latent infection offers improved control. A recent study advocates the use of IFN-g 
release assays to detect latent TB infection in immigrants to the UK under 35 years of age and 
suggests that such a program would be most cost effective if targeted at new entrants from 
high burden countries. We discuss these findings in the light of recently updated UK and 
European guidelines. We conclude that while action to contain TB in the UK is urgently needed, 
further evidence is required to assess the impact and cost–effectiveness of screening algorithms 
for latent infection.
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prior to initiating prophylactic treatment to 
avoid the emergence of drug resistance through 
inappropriate therapy. In addition, a negative 
IGRA result does not exclude Mtb infection or 
active TB disease [2,3]. A further consideration is 
that treatment for latent infection incurs a risk 
of toxic side effects and UK guidelines recom-
mend that individual risks and benefits be con-
sidered before treatment is offered to people over 
35 years of age [103]. The UK NICE guidelines 
regarding latent TB and screening new entrants 
were revised in March 2011 [103]. We discuss 
the findings from the study by Pareek and col-
leagues in the light of the new NICE recom-
mendations and comment on implications for 
TB control in the UK, highlighting areas that 
require further research. 
Summary of methods & results 
Pareek and colleagues undertook analysis of 
data collected in three referral centers in the UK 
that have implemented the QuantiFERON-TB 
Gold In-Tube for screening foreign born persons 
for latent Mtb infection. The centers studied 
were Westminster (London, UK), Leeds and 
Blackburn and all participants were aged 35 years 
or younger and within the first 5 years of their 
arrival in the UK. Symptomatic individuals and 
Tuberculosis (TB) is a serious and emerging 
problem in the UK where over 9000 cases are 
recorded annually [101]. Data from the Health 
Protection Agency shows that over 70% of UK 
TB cases are born outside of the country lead-
ing to the supposition that treatment of latent 
Mycobacterium tuberculosis (Mtb) infection in 
immigrants would, by reducing the progres-
sion to active disease, decrease the prevalence of 
TB [101]. The recently published article by Pareek 
and colleagues investigates the cost–effective-
ness of a strategy for screening immigrants for 
latent Mtb infection using an IFN-g release assay 
(IGRA) [1]. There are two commercial IGRAs 
currently available, the QuantiFERON®-TB 
Gold In-Tube assay (Cellestis Ltd., Victoria, 
Australia) and the T-SPOT®.TB (Oxford 
Immunotec, Oxfordshire, UK) [102]. They 
measure IFN-g released following the incuba-
tion of patient blood with antigens specific to 
Mtb; early secretory antigenic target-6, culture 
filtrate protein 10, and the TB7.7 antigens. A 
positive test indicates an immune response to the 
Mtb antigens and it is not yet known how long 
an IGRA remains positive following infection, 
or following the successful treatment of active 
TB. IGRAs are not specific to latent infection 
and it is necessary to exclude active TB disease 
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those with a positive IGRA test were assessed for active TB by chest 
radiography and further clinical assessment. Of 1361 immigrants 
screened, five (0.04%) were found with active TB. Of 1229 indi-
viduals included in the final analysis, 245 (20%) were found posi-
tive with the IGRA test. Logistic regression found the factors asso-
ciated with a positive IGRA test result were male sex (p = 0.046), 
increasing age (p < 0.0001) and TB incidence in the country of 
origin (p = 0.0006). Lack of data prevented Mycobacterium bovis 
bacillus Calmette–Guérin (BCG) vaccine status and HIV infec-
tion in the multivariate analysis. The authors present the yield of 
positive IGRA test results stratified by the prevalence of TB in the 
country of origin and by age. The new NICE guidelines recom-
mend offering a test for latent infection being included to new 
arrivals under the age of 35 years from countries with a TB preva-
lence greater than 40 cases per 100,000 of the population [103]. A 
total of 99% of the immigrants tested fell into this category and 
no additional latent infections were detected in the 13 immigrants 
who originated in countries with low prevalence of TB. 
Economic analysis was undertaken from the health provider 
perspective on a hypothetical cohort of 10,000 immigrants. The 
number of TB cases averted during 20 years following therapy 
for latent infection was estimated using data derived from a sys-
tematic review of the literature. A decision tree was constructed 
and sensitivity analysis undertaken. An estimated 95 active TB 
cases were predicted to occur if no treatment for latent infection 
was given, with an estimated associated cost to the health service 
of GB£600,000. Screening immigrants according to the 2011 
NICE guidelines reduced the predicted number of active cases 
to 51, but at a cost of more than £1.5 million. Cost–effectiveness 
increased if screening was restricted to immigrants from countries 
with higher burdens of TB. With TB incidence thresholds of 
250, 150 and 40 per 100,000, the incremental cost–effectiveness 
ratio per active case averted was £17,956, £208,819 and £29,403, 
respectively. The incremental cost–effectiveness ratio per case 
averted for screening all 16–35 year olds, regardless of country 
of origin, was £101,938. 
Expert commentary
Guidance issued in 2011 by the European Centre for Disease 
Prevention and Control suggests that to identify individuals 
with latent Mtb infection for whom preventive treatment could 
be considered, IGRAs should be used as part of an overall risk 
assessment [2]. NICE guidelines advocate their use when screen-
ing new entrants from high burden countries. A recent survey of 
primary care organizations in the UK demonstrated considerable 
heterogeneity in screening algorithms and in the proportion of 
immigrants found with latent TB infection, ranging from 4 to 
33% [4]. Pareek and colleagues have shown that the cost–effective-
ness of screening for latent infection may be enhanced by selective 
testing of immigrants at the highest risk and that the prevalence of 
TB in the country of origin is a key factor [1]. However, sensitivity 
analysis demonstrated that accurate estimates of some components 
in their decision model were crucial. A critical factor was the pro-
portion progressing to active disease over the 20-year period. This 
outcome will be influenced by a number of factors that were not 
taken into account during the study, including the prevalence of 
confounding conditions such as coinfection with HIV. An addi-
tional consideration is the length of time those tested remained 
resident in the UK as it is likely that a proportion of immigrants 
with latent infection will leave the UK before progressing to active 
disease. Approximately a third of UK immigrants are students, of 
which two-thirds expect to stay in the country for less than 2 years 
and only 6% expect to stay more than 4 years [104]. In addition, the 
model did not take into account TB cases in immigrants arising 
from exposure subsequent to their arrival in the UK – for example, 
during visits to their home country. The specificity of the IGRA 
test was also important and further research is needed to compare 
the efficacy of screening algorithms in the UK [5]. 
In general, IGRA tests are commercial laboratory-based biologi-
cal assays that require the transportation of blood samples to the 
laboratory under controlled conditions. It might be expected that 
additional costs would be incurred when compared with other 
methods of testing for latent infection, such as the tuberculin skin 
test. The lack of a test able to differentiate latent Mtb infection 
from active clinical disease is a hindrance to TB control. Of par-
ticular concern is the exclusion of extrapulmonary disease. Rates 
of resistance to isoniazid are elevated in extrapulmonary cases in 
the UK and inappropriate use of latent monotherapy would exac-
erbate this problem [101]. The majority of persons with a positive 
IGRA test will not progress to active disease and a test that predicts 
with greater accuracy the likelihood of developing TB would be of 
great benefit. Ideally such a test should be a point-of-care testing 
device that would avoid referral to a laboratory [6]. 
There were an estimated 590,000 immigrants to the UK during 
2008, and excluding persons from the EU, 
the majority originate from countries in Asia 
and Africa with high burdens of TB [104]. 
The number arriving from four high bur-
den countries is presented in Table 1. With 
an estimated 84% sensitivity screening by 
IGRA would leave a considerable pool of 
undetected latent infection in these popula-
tions. Approximately half the immigrants 
to the UK are older than 35 years of age. In 
their article, Pareek and colleagues do not 
consider a strategy to prevent TB in this 
population. A proportion of immigrants 
Table 1. Estimated number of immigrants to the UK arriving from 
four countries with a high burden of TB during 2008. 
Country of last 
residence
Immigrants to the UK (1000s) Estimated TB incidence per 
100,000 population
India 47 168
Pakistan 19 231
South Africa 20 960
China 18 97
Compiled with data from the UK Migration Statistics 2008 Annual Report and WHO Global TB control 
report 2010 [103,105].
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may be screened though other programs. NICE guidelines cur-
rently recommend the screening of health service employees who 
have recently arrived from high-incidence countries and all per-
sons at risk who are immunocompromised. Other inventions that 
may contribute to a reduction in the burden of TB in the UK 
include enhanced contact tracing and screening for other high-
risk groups. It is also important that awareness is increased among 
health professionals and community organisations. Stigmatization 
of  immigrant groups and individuals must be avoided. 
Five-year view
The unacceptable level of TB in the UK demands action. 
Screening for recently arrived immigrants for latent disease 
would offer a partial solution. However, the impact on case noti-
fication rates of screening a limited age range (under 35 years 
of age) remains unclear and will depend on factors that have 
not been examined in the article by Pareek and colleagues. The 
number of UK cases averted by screening new entrants will be 
influenced by the accuracy of the test used and the length of 
stay of those screened. Referral patterns and the contribution of 
alternative and complementary screening strategies need to be 
considered. The impact of post-arrival exposure also needs to 
be assessed, where TB may result from infection or reinfection 
some time after arrival in the UK. Current testing strategies 
are restricted by the need to use sophisticated laboratory-based 
tests and the difficulties of differentiating latent infection from 
active disease. The development of improved tests is awaited but 
until the arrival of accurate point-of-care diagnostic tests and 
technology that can predict progression to active disease it is 
necessary to implement screening algorithms that are appropri-
ate and effective. Screening for latent infection in new arrivals 
at risk of TB should be expanded, and research undertaken, in 
order to establish best practice. The proposed reorganisation 
of commissioning within NHS may alter referral patterns and 
coordination of TB control in the UK. It is important that the 
changes are tailored to assist and promote activities to reduce 
the incidence of TB. 
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Key issues
• TB is a global health problem and high incidences are observed in many countries in Africa and Asia. 
• In the UK, case-notification rates are increasing and London now has levels of disease exceeding 44 per 100,000 of the population. 
• Over 70% of incident TB cases in the UK are in people born overseas and NICE guidelines issued in 2011 recommend screening for 
latent infection in new entrants under 35 years of age from countries with a TB prevalence greater than 40 per 100,000.
• The efficiency of screening is adversely affected by the lack of a test that can differentiate latent infection and active disease. This is 
particularly a concern with extrapulmonary forms of TB that are difficult to diagnose. 
• Data analysis by Pareek and colleagues collected in UK referral centers that screen new entrants under 35 years of age for latent 
infection revealed that male sex, increasing age and increased incidence of TB in country of origin were associated with a positive 
test result. 
• Incremental cost–effectiveness ratios per active case averted when using an IFN-g release assay to screen for latent TB demonstrated 
that targeted screening of individuals from high burden countries improved the cost–effectiveness of the intervention.
• Further evidence is needed regarding the effectiveness and impact of screening strategies for latent infection in immigrants in the UK. 
Evidence is also needed regarding the contribution of other components of the strategy to control TB in the UK.
• There is uncertainty as to the future administration of TB control in the UK owing to the proposed restructuring of commissioning 
within the public health service.
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